The study retrospectively analyzed clinical data from 113 prostate cancer patients treated at the UCLA Jonsson Comprehensive Cancer Center. All participants underwent PSMA PET/CT scans for recurrent disease evaluation, revealing critical insights about the anatomical extent and biological behavior of residual or metastatic lesions. PSMA PET/CT, by targeting membrane antigen expression on prostate cancer cells, provides superior sensitivity and specificity over conventional imaging, enabling early detection even at low PSA levels. This molecular imaging modality has rapidly become a vital tool for pinpointing occult disease sites post-prostatectomy and determining appropriate salvage therapy strategies.

Findings indicated that patients with no visible disease on PSMA PET/CT (classified as T0N0M0) experienced the most favorable progression-free survival. For this subgroup, whole-pelvis radiotherapy (WPRT) did not show significant benefits beyond prostate bed radiotherapy alone, suggesting that extensive radiation fields might be unnecessary when imaging reveals no overt disease. This emphasizes the potential to minimize overtreatment and associated toxicities by leveraging precise imaging.

Conversely, individuals with local, visible recurrence confined to the prostate bed (TrN0M0) demonstrated significant PFS improvement when treated with WPRT compared to prostate bed radiotherapy alone. This highlights the importance of incorporating imaging evidence of localized recurrence into radiation planning, supporting more aggressive therapy aimed at controlling subclinical micrometastases within the pelvic lymphatic drainage region. Such data underscore the principle that therapeutic volumes should be modulated based on anatomically accurate tumor burden assessment.

In cases where PSMA PET/CT revealed nodal or distant metastatic disease, the addition of androgen deprivation therapy (ADT) correlated with notably better PFS outcomes. ADT—a cornerstone systemic therapy targeting androgen receptor signaling—appears especially critical in controlling biologically aggressive and disseminated prostate cancer identified by advanced imaging. This multidimensional strategy combining imaging-guided radiotherapy with systemic hormonal therapy exemplifies personalized oncology, maximizing efficacy while potentially sparing patients from unnecessary toxicity.

John Nikitas, MD, the study’s lead investigator from UCLA, emphasized that routine utilization of PSMA PET/CT scans following biochemical recurrence provides clinicians with indispensable data that frequently alter treatment recommendations. In contrast to PSA levels alone, which were not strongly predictive of response to salvage therapies, PET/CT imaging delineates disease distribution and guides decisions that influence long-term outcomes. His remarks underscore the paradigm shift from relying solely on serum biomarkers toward integrated molecular imaging in prostate cancer care.

Beyond survival metrics, the study suggests that PSMA PET/CT can spare patients from the side effects of overly aggressive or inappropriate therapies. By objectively stratifying recurrent disease patterns—ranging from absent to localized versus metastatic—clinicians can select treatment intensities that provide optimal therapeutic gain without excessive morbidity. This precision approach enhances quality of life for men undergoing salvage therapy.

E. Christopher Dee, MD, from Memorial Sloan Kettering Cancer Center, who was not involved in the study, commented on the transformative potential of PSMA PET imaging. He pointed out that this technology enables a shift from one-size-fits-all radiation regimens to personalized treatments informed by anatomy and tumor biology. He highlighted that detecting cancer locations even at low PSA levels can fundamentally change practice patterns and improve patient outcomes. His insights further validate the clinical value of integrating functional molecular imaging into secondary and salvage prostate cancer management.

This research opens new avenues for prospective clinical trials aimed at refining the synergistic roles of imaging, radiotherapy, and systemic treatments in the salvage setting. The ability to visualize occult disease burdens non-invasively offers opportunities to test novel therapeutic combinations and dosing regimens with unprecedented precision and adaptive strategies aligned to changing tumor landscapes detected by PSMA PET/CT.

Furthermore, the adoption of PSMA PET/CT has implications beyond improved clinical outcomes. It promotes cost-effectiveness by avoiding unnecessary treatments and associated complications, thereby potentially reducing healthcare system burdens. The enhanced accuracy in staging and treatment response monitoring also contributes to more efficient resource allocation in oncology care.

Mechanistically, PSMA PET/CT imaging capitalizes on the overexpression of PSMA on prostate cancer cells and near absence in most normal tissues, generating high tumor-to-background contrast. Coupled with hybrid PET/CT technology, it allows simultaneous anatomical localization and molecular characterization, surpassing conventional imaging modalities such as bone scans or CT alone. This dual modality approach provides comprehensive insights that inform clinical decision-making with unparalleled granularity.

Overall, this study marks a significant milestone in the journey toward precision oncology for prostate cancer recurrence. It exemplifies how integrating molecular imaging with conventional treatment paradigms can tailor interventions to individual disease biology and distribution, ultimately enhancing patient outcomes and quality of life. As PSMA PET/CT becomes more widely accessible, its impact on guiding salvage radiotherapy and systemic treatment strategies is poised to expand exponentially, fostering more personalized, effective, and less toxic prostate cancer care worldwide.

Subject of Research: Prostate cancer patients with biochemical recurrence after radical prostatectomy

Article Title: Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

News Publication Date: February 9, 2026

Web References:

• Full article and commentary available at JNCCN.org
• Commentary titled “The Last Word” at JNCCN.org

Image Credits: Credit to NCCN

Keywords: Prostate cancer, PSMA PET/CT, salvage radiotherapy, biochemical recurrence, androgen deprivation therapy, progression-free survival, molecular imaging, personalized oncology, radiation therapy, prostate-specific antigen, metastatic disease, precision medicine

A recent publication featured a compelling response from Bilen, Lowentritt, Khilfeh, and colleagues, who tackle the intricacies surrounding patient outcomes between these two treatment methodologies. Their response to a letter to the editor on the subject demonstrates the depth of analysis required when evaluating treatment efficacy. This correspondence comes amid growing scrutiny and excitement within the oncology field over therapeutic strategies that could either maximize patient survival or lead to new paradigms in treatment approaches.

At its core, the comparative analysis hinges on clinical endpoints that define success in cancer treatment: progression-free survival, overall survival, and quality of life metrics. Both apalutamide and enzalutamide have been shown to prolong life by delaying cancer progression. However, the nuances of how each drug achieves this highlight crucial differences in mechanisms of action that warrant further exploration.

Apalutamide operates as a potent androgen receptor inhibitor, effectively obstructing testosterone’s ability to fuel cancer cell growth. Its relatively recent approval for metastatic castration-sensitive prostate cancer marks a significant milestone in the therapeutic landscape. Conversely, enzalutamide, another established androgen receptor antagonist, also blocks androgen signaling but does so in a slightly different manner, providing patients with an alternative pathway to find effective treatment.

As Bilen and colleagues articulate, understanding the implications of these differences is paramount in guiding treatment decisions. They note that a merely superficial comparison of survival statistics may obscure underlying variances in patient responses. The insight shared through their correspondence calls for a diligent examination of the data, highlighting the need for comprehensive analyses that go beyond standard metrics to include the diverse patient populations affected by these treatments.

Furthermore, Bilen et al. emphasize that ongoing clinical trials are crucial for elucidating these distinctions. They underscore how real-world evidence can either reinforce or challenge current assumptions, ultimately shaping patient management strategies and influencing future research funding priorities. As they navigate through the complexities of conflicting data, their response serves as a clarion call to clinicians and researchers alike: to deepen their understanding rather than merely accept prevailing narratives.

The letter also highlights concerns over the potential for bias in interpretations of trial data, expressing that not all studies are designed equally. Statistical significance, while essential, does not tell the entire story; thus, thorough scrutiny of methodology, study populations, and treatment adherence rates becomes essential in forming a consensus. As advocates for rigorous scientific inquiry, the authors underscore their commitment to enhancing patient care through advocacy for robust clinical evaluation standards.

Another crucial point raised in the correspondence is the growing collection of patient-reported outcomes, which adds a vital dimension to treatment evaluation. Patients’ experiences with drug tolerance, side effects, and overall wellbeing can markedly influence treatment trajectories. Bilen and his co-authors stress that incorporating these narratives into the clinical decision-making process can bridge the gap between data-driven protocols and individualized patient care.

Moreover, the future of metastatic castration-sensitive prostate cancer therapy may hinge on an integrated approach encompassing both pharmacologic and non-pharmacologic interventions. Bilen et al. advocate for holistic methodologies that leverage the strengths of nutritional science, psychosocial support, and innovative therapies alongside traditional drug regimens. This can unleash the potential for more comprehensive patient management strategies, aiming for synergistic effects that enhance life quality while pursuing longevity.

As we embark on this journey of nuanced understanding, it is paramount that the dialogue encompassing apalutamide versus enzalutamide continues unabated. The conversation must extend beyond academic confines to engage active participation from patients, caregivers, and health systems, transforming research into actionable insights. In doing so, we can revolutionize prostate cancer management, breathing new life into treatment strategies and clinical practice.

In conclusion, the spirited exchange initiated by Bilen, Lowentritt, Khilfeh, and Khilfeh serves as both a reminder and a tour de force that rigorous scientific discourse is vital for the advancement of oncology. The investigation into the raised issues surrounding apalutamide and enzalutamide illuminates the multifaceted nature of cancer treatment, highlighting that the quest for improved survival is as much about data as it is about patient perspectives. As this debate continues to unfold, the ultimate beneficiaries will undoubtedly be the patients who navigate these complex choices in their fight against prostate cancer.

Ultimately, one can draw the insight that navigating drug choices in the face of metastatic castration-sensitive prostate cancer should not be a quest to identify the superior drug but rather to develop a treatment paradigm that is robust, personalized, and patient-centered. The key will lie in harnessing the knowledge gained from ongoing studies and leveraging patient experiences to drive the next generation of prostate cancer therapies.

Subject of Research: Comparative effectiveness of apalutamide vs. enzalutamide in metastatic castration-sensitive prostate cancer.

Article Title: Response to Letter to the Editor Regarding: ‘Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer’.

Article References:
Bilen, M.A., Lowentritt, B., Khilfeh, I. et al. Response to Letter to the Editor Regarding: ‘Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer’. Adv Ther (2025). https://doi.org/10.1007/s12325-025-03436-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12325-025-03436-9

Keywords: prostate cancer, apalutamide, enzalutamide, overall survival, metastatic castration-sensitive prostate cancer, clinical trials, patient-reported outcomes, cancer treatment strategies.

Prostate cancer remains the second most prevalent malignancy among men globally, often presenting a formidable challenge when it recurs after initial treatment. Oligorecurrent prostate cancer, characterized by a small number of new metastatic lesions, demands precise and effective therapeutic interventions. SBRT, a form of high-precision radiation that targets tumors while sparing surrounding healthy tissue, has become the standard for managing these cases. However, many patients eventually experience relapse, primarily due to microscopic disease invisible on conventional imaging.

To address this, the UCLA-led LUNAR phase 2 trial investigated whether incorporating a PSMA-targeted radioligand, specifically the molecule 177Lu-PNT2002, prior to SBRT could better eradicate both visible and occult prostate cancer cells. Prostate-specific membrane antigen (PSMA) is a protein abundantly expressed on prostate cancer cells, making it an ideal target for radioligand therapies. Unlike traditional radiation, radioligand therapy delivers targeted radiation via radioactive isotopes linked to molecules that bind directly to cancer cells, minimizing collateral damage to healthy tissues.

The trial enrolled 92 men with oligorecurrent prostate cancer and randomly assigned them to two groups. The control arm received SBRT alone, while the experimental arm received two doses of 177Lu-PNT2002 before SBRT. Patients were monitored through prostate-specific antigen (PSA) blood tests and advanced PSMA PET imaging to evaluate disease progression. Remarkably, those treated with the combination therapy exhibited a median progression-free survival of 17.6 months, more than twice that of the SBRT-only group, which demonstrated 7.4 months.

This substantial improvement translated into a 63% reduction in the combined risk of cancer progression, initiation of hormone therapy, or death. Importantly, the addition of 177Lu-PNT2002 delayed the initiation of androgen deprivation therapy (ADT)—a cornerstone treatment for advanced prostate cancer known for its severe side effects such as fatigue, sexual dysfunction, and bone density loss. Men receiving the combination therapy enjoyed a median of 24.3 months before hormone therapy became necessary, compared to 14.1 months in the SBRT-alone cohort.

The success of this combined modality stems not only from its capacity to target PSMA-expressing cancer cells visible on PET scans but also from its potential to eradicate microscopic disease lingering beneath the detection threshold. By harnessing PSMA PET imaging to precisely guide SBRT targeting and coupling it with radioligand therapy, the researchers created a dual-attack strategy that addresses both macroscopic and microscopic cancer deposits.

Additionally, the LUNAR trial delved into biological markers that could predict patient responses to treatment. The researchers analyzed T cell receptor changes post-SBRT, immunological shifts associated with improved clinical outcomes. Furthermore, a gene expression signature encompassing 20 genes linked to immune function and DNA repair differentiated patients at higher risk of disease progression from those more likely to benefit from therapy, opening avenues toward personalized treatment approaches.

Despite the profound benefits observed, the trial underscored ongoing challenges, as 64% of men still experienced disease progression. This high relapse rate highlights the complexity of micrometastatic prostate cancer and suggests the need for further refinements in both therapeutic delivery and precision targeting.

Dr. Amar Kishan, the executive vice chair of radiation oncology and co-director of the cancer molecular imaging, nanotechnology, and theranostics program at UCLA, emphasized the significance of these findings: “Our research provides pivotal proof of principle that radioligand therapy can be effectively and safely integrated earlier in prostate cancer treatment, offering patients meaningful delays in disease progression and hormone therapy initiation without additional toxicity.”

Moreover, Dr. Jeremie Calais, the trial’s senior author and director of the Ahmanson Translational Theranostics Division, highlighted the synergy achieved through collaboration between radiation oncology and nuclear medicine. This interdisciplinary approach exemplifies the promise of theranostics—a field combining diagnostic imaging and targeted therapy—to revolutionize cancer care paradigms.

The safety profile of the combination therapy was also encouraging, with minimal adverse effects reported, reinforcing its potential for broader clinical application. Nevertheless, the investigators acknowledge the necessity for longer-term follow-up and exploration of strategies to enhance response rates, such as optimizing dosing schedules or combining with immunotherapies.

This study not only propels forward the clinical utility of PSMA-targeted radioligand agents beyond advanced metastatic settings but also redefines the therapeutic landscape for men with oligorecurrent disease. By extending progression-free survival and postponing hormone therapy, this approach promises to improve both survival and quality of life for countless patients worldwide.

Funded by Lantheus, the LUNAR trial represents a milestone in prostate cancer research, illuminating a new path for early intervention that leverages molecular targeting and state-of-the-art imaging to outmaneuver one of the most common and insidious cancers affecting men today.

Subject of Research: Prostate cancer treatment using PSMA-targeted radioligand therapy combined with stereotactic body radiotherapy (SBRT).

Article Title: New Radioligand Therapy Combined with Radiotherapy Doubles Progression-Free Survival in Recurrent Prostate Cancer

News Publication Date: 2025

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• 2025 ASTRO Annual Meeting Session: https://amportal.astro.org/sessions/ct-01-21645/177-lutetium-psma-neoadjuvant-to-ablative-radiotherapy-for-oligorecurrent-prostate-cancer-pri-109077
• Dr. Amar Kishan Profile: https://www.uclahealth.org/providers/amar-kishan
• Dr. Jeremie Calais Profile: https://www.uclahealth.org/cancer/members/jeremie-calais

Keywords: Prostate cancer, PSMA-targeted radioligand therapy, stereotactic body radiotherapy, oligorecurrent disease, progression-free survival, androgen deprivation therapy, theranostics, prostate-specific membrane antigen, 177Lu-PNT2002, molecular imaging, cancer treatment innovations.